Pleural Mesothelioma Prognosis

In this article, we will discuss Prognosis of Malignant Pleural Mesothelioma. So, let’s get started.

Prognosis

Despite major developments in assessment and treatment, the
prognosis in mesothelioma remains poor (range 2-86 months). Various series have reported survival data which remain generally disappointing, but in most series there are a small number of unexpected long term survivors. Various prognostic factors permit a degree of refinement of survival prediction. Advancing age, extensive disease, and sarcomatoid or biphasic histological subtypes are independent adverse risk factors. Long term survivors tend to be almost exclusively from the epithelioid group.

Classification of pleural cancer treatment

Curative intent
• Surgery
• Chemotherapy
• Systemic
• Intracavitary
• Radiotherapy
• Multimodality therapy

Active symptom control
• Breathlessness
• Analgesic measures for chest pain
• Pharmacological
• Non-pharmacological
• Tumour seeding in the chest wall
• Miscellaneous

Survival Rate of MPM

A relative survival rate compares people with the same type and stage of malignant pleural mesothelioma (MPM) to people in the overall population. For example, if the 5-year relative survival rate for a specific stage of MPM is 40%, it means that people who have that cancer are, on average, about 40% as likely as people who don’t have that cancer to live for at least 5 years after being diagnosed.

The American Cancer Society relies on information from the SEER database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer. The SEER database tracks 5-year relative survival rates for MPM in the United States, based on how far the cancer has spread. The SEER* database, however, does not group cancers by AJCC TNM stages (stage 1 stage 2. stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:

Localized: The cancer is limited to the pleura.
Regional: The cancer has spread to nearby structures or to nearby lymph nodes.
Distant: The cancer has spread to distant parts of the body such as the liver, bones or pleura on the other side of the body.

5-year relative survival rates for malignant pleural mesothelioma
(Based on people diagnosed with MPM between 2010 and 2016.)

SEER Stage – 5-Year Relative Survival Rate

Localized – 18%
Regional – 12%
Distant – 7%
AISEER stages combined – 10%

These numbers apply only to the stage of the cancer when it is first diagnosed. They do not apply later on if the cancer grows, spreads, or comes back after treatment. These numbers don’t take everything into account. Survival rates are grouped based on how far the cancer has spread, but your age, overall health, how resectable the cancer is type of mesothelioma , how well the cancer responds to treatment, and other factors can also affect your outlook.

*SEER= Surveillance, Epidemiology, and End Results

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.